The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Tumor-Associated Macrophages: From Mechanisms to Therapy
Open accessAbstract
The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Many therapy strategies have attempted to alter the polarization of macrophages’ “re-programming” or prevent monocyte tumor infiltration (Noy and Pollard, 2014).”
From Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review (2021) · cites this paper as Noy and Pollard, 2014
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [167]
In the citing paper
“The production of colony stimulating factor 1 (CSF-1; also known as macrophage colony stimulating factor) by BCCs, has been reported to stimulate the recruitment of macrophages to primary breast tumors, leading to the secretion by tumor-associated macrophages (TAMs) of epidermal growth factor, which binds to its cognate receptor on BCCs to stimulate invasion and metastasis [36–38].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79 · cited 2×
“Interestingly, CSF1 upregulates TIE2 on TAMs (Forget et al., 2014) indicating a link between CSF1, TIE2 macrophages, and the induction of the angiogenic switch.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…the ways in which the microenvironmental support to tumors is the acquisition of a vasculature that provides oxygenation, as well as the nutrition and waste disposal required for growth above a certain size in a process often referred to as the ‘‘angiogenic switch’’ (Hanahan and Weinberg, 2011).”
BackgroundCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 4×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundInfluentialMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“…SPARC) that increases tumor cell-ECM interaction and thus migration (Sangaletti et al., 2008), Cathepsin proteases that remodel the matrix and release sequestered growth factors (Laoui et al., 2011; Quail and Joyce, 2013) and TGF-b that promotes EMT of the invading tumor cells (Bonde et al., 2012).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“TheseM-MDSCs have greater immunosuppressive potency than the granulocytic ones and are further defined as F4/80+ a marker also found on inflammatory monocytes (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012). above strongly support targeting the destruction or redifferentiation of macrophages as an important part of combinatorial therapies in human cancer patients.”
BackgroundAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“…the activated macrophages responding to IFN-g, TNF-a, and Toll-like receptor 4 (TLR4) activation capable of killing pathogens through mechanisms such as iNOS, and (2) alternatively activated macrophages responding to IL-4 and IL-13 involved in antiparasitic immunity and in asthma (Gordon, 2003).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,338 · cited 11×
“Furthermore, in most large-scale transcriptome analysis, macrophages have a mixed phenotype expressing both M1 and M2 markers (Qian and Pollard, 2010).”
BackgroundInfluentialSelf-citation
Flagged first, then by citations
2 of the 136 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,010
Kim, H., Chung, H., Kim, J., Choi, D., Shin, Y., Kang, Y. G., Kim, B., Seo, S., Chung, S. H., & Seok, S. H. (2019) · Advanced Science · doi:10.1002/advs.201900195 · Cited by 118
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Agarwal, P., Hwang, B.-J., Acharya, C. R., Shuptrine, C. W., Wang, T., Wei, J.-P., Yang, X. Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131882 · Cited by 120
Matsuzaki, S., Klar, M., Matsuzaki, S., Roman, L. D., Sood, A. K., & Matsuo, K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.043 · Cited by 120
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Swamydas, M., Murphy, E. V., Ignatz-Hoover, J. J., Malek, E., & Driscoll, J. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01234-2 · Cited by 121
Association between pH regulation of the tumor microenvironment and immunological state
Hosonuma, M., & Yoshimura, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175563 · Cited by 129
Mattiola, I., Pesant, M., Tentorio, P., Molgora, M., Marcenaro, E., Lugli, E., Locati, M., & Mavilio, D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500325 · Cited by 122
Leukocyte trafficking in tumor microenvironment
Prete, A. D., Schioppa, T., Tiberio, L., Stabile, H., & Sozzani, S. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.004 · Cited by 122
Therapeutic Antibodies against Intracellular Tumor Antigens
Trenevska, I., Li, D., & Banham, A. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01001 · Cited by 113
Müller, E., Speth, M. T., CHRISTOPOULOS, P. F., Lunde, A., Avdagic, A., Øynebråten, I., & Corthay, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02520 · Cited by 118
Joshi, S., & Durden, D. L. (2019) · Journal of Oncology · doi:10.1155/2019/5245034 · Cited by 120
Lin, X., Zhou, L., Liu, C., Zeng, F., Yuan, Y., Zhou, Q., Li, S., Wu, Y., Wang, J., Wu, D., et al. (2021) · EMBO Reports · doi:10.15252/embr.202052124 · Cited by 120
Cao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 120
Cell membrane-coated nanomaterials for cancer therapy
Zeng, S., Tang, Q., Xiao, M., Tong, X., Yang, T., Yin, D., Lei, L., & Li, S. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100633 · Cited by 118
Pierini, S., Gabbasov, R. T., Oliveira-Nunes, M. C., Qureshi, R., Worth, A. M., Huang, S., Nagar, K. K., Griffin, C., Lian, L., Yashiro–Ohtani, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55770-1 · Cited by 123
“Although several studies have shown that macrophage phenotype is context-dependent 48,49 , monocyte-derived tumor-associated macrophages often contribute to tumor progression and are associated with poor clinical prognosis 50,51 .”
Emerging Roles for Eosinophils in the Tumor Microenvironment
Reichman, H., Karo-Atar, D., & Munitz, A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.002 · Cited by 116
Zhao, J., Huang, F., He, F., Gao, C.-C., Liang, S.-Q., Ma, P., Dong, G., Han, H., & Qin, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2019 · Cited by 115
Guillerey, C., Nakamura, K., Vučković, S., Hill, G. R., & Smyth, M. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2135-z · Cited by 121
The Process and Regulatory Components of Inflammation in Brain Oncogenesis
Mostofa, A., Punganuru, S. R., Madala, H. R., Al-Obaide, M., & Srivenugopal, K. S. (2017) · Biomolecules · doi:10.3390/biom7020034 · Cited by 121
Baghdadi, M., Endo, H., Takano, A., Ishikawa, K., Kameda, Y., Wada, H., Miyagi, Y., Yokose, T., Ito, H., Nakayama, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18796-8 · Cited by 118
Chen, X., Wu, S., Yan, R.-M., Fan, L., Yu, L., Zhang, Y., Wei, W., Zhou, C., Wu, X., Zhong, M., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22936 · Cited by 115
A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma
Liu, H., & Weng, J. (2022) · Gene · doi:10.1016/j.gene.2022.146325 · Cited by 115
Galletti, G., Scielzo, C., Barbaglio, F., Rodríguez, T. V., Riba, M., Lazarević, D., Cittaro, D., Simonetti, G., Ranghetti, P., Scarfò, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.042 · Cited by 111
Sun, W., Wei, F., Li, W.-J., Wei, J.-W., Zhong, H., Wen, Y., Lei, W., Chen, L., Li, H., Lin, H., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.329 · Cited by 114
Yagi, T., Baba, Y., Okadome, K., Kiyozumi, Y., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.018 · Cited by 113
Rick, J. W., Chandra, A., Ore, C. L. D., Nguyen, A. T., Yagnik, G., & Aghi, M. K. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.002 · Cited by 125
Targeting tumor‑associated macrophages in the tumor microenvironment (Review)
Zhou, K., Cheng, T., Zhan, J., Peng, X., Zhang, Y., Wen, J., Chen, X., & Ying, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12097 · Cited by 122
Petty, A. J., Dai, R., Lapalombella, R., Baiocchi, R. A., Benson, D. M., Li, Z., Huang, X., & Yang, Y. (2021) · JCI Insight · doi:10.1172/jci.insight.146707 · Cited by 117
Compensatory angiogenesis and tumor refractoriness
Gacche, R. N. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.14 · Cited by 117
Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers
Ma, L., Cross, T.-W., Wallig, M. A., Dobrucki, I. T., Dobrucki, L. W., Nelson, E. R., Swanson, K. S., & Smith, A. M. (2016) · ACS Nano · doi:10.1021/acsnano.6b02878 · Cited by 118
Koru‐Sengul, T., Santander, A. M., Miao, F., Sanchez, L. G., Jordà, M., Glück, S., Ince, T. A., Nadji, M., Chen, Z., Penichet, M. L., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3847-3 · Cited by 117
Zhang, C., Yu, X., Gao, L., Zhao, Y., Lai, J., Lu, D., Bao, R., Jia, B., Zhong, L., Wang, F., et al. (2017) · Theranostics · doi:10.7150/thno.20999 · Cited by 113
Nam, G., Lee, E. J., Kim, Y. K., Hong, Y., Choi, Y., Ryu, M., Woo, J., Cho, Y., Ahn, D. J., Yang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04607-9 · Cited by 113
Targeted Theranostic Nanoparticles for Brain Tumor Treatment
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040181 · Cited by 117
Rho-Associated Coiled-Coil Kinase (ROCK) in Molecular Regulation of Angiogenesis
Liu, J., Wada, Y., Katsura, M., Tozawa, H., Erwin, N. A., Kapron, C. M., Bao, G., & Liu, J. (2018) · Theranostics · doi:10.7150/thno.30305 · Cited by 117
Xiao, W., Liu, L., Li, X., Wang, Y., Guo, X., Zhao, J., & Zhou, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.021 · Cited by 113
Li, K., Lu, L., Xue, C., Liu, J., He, Y., Zhou, J., Xia, Z., Dai, L., Luo, Z. Y., Mao, Y., et al. (2019) · Nanoscale · doi:10.1039/c9nr06505a · Cited by 113
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
Macrophages Actively Transport Nanoparticles in Tumors After Extravasation
Lin, Z. P., Nguyen, L. N. M., Ouyang, B., MacMillan, P., Ngai, J., Kingston, B. R., Mladjenovic, S. M., & Chan, W. C. W. (2022) · ACS Nano · doi:10.1021/acsnano.1c11578 · Cited by 119
Zhao, Y., Pan, Y., Zou, K., Lan, Z., Cheng, G., Mai, Q., Cui, H., Meng, Q., Chen, T., Rao, L., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.04.011 · Cited by 116
The Warburg effect: a score for many instruments in the concert of cancer and cancer niche cells
Jaworska, M., Szczudło, J., Pietrzyk, A., Shah, J., Trojan, S., Ostrowska, B., & Kocemba‐Pilarczyk, K. A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00504-1 · Cited by 128
“In the presence of lactate, the anti-tumor function of M1 macrophages is inhibited by reducing the expression of IL-6 (interleukin 6), IL–1 (interleukin 1), iNOS (inducible nitric oxide synthase), and TNF (tumor necrosis factor) [72, 74], while inactivated macrophages undergo an induced polarization process changing t…”
BackgroundThe role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach
Adjei, I. M., & Sharma, B. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6010081 · Cited by 115
Liu, L., Yu, Y., & Zhu, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109096 · Cited by 112
Lan, H., Liu, Y., Liu, J., Wang, X., Guan, Z., Du, J., & Jin, K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00961 · Cited by 112
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Metabolism and TAM functions—it takes two to tango
Mazzone, M., Menga, A., & Castegna, A. (2017) · FEBS Journal · doi:10.1111/febs.14295 · Cited by 115
Kubli, S. P., Bassi, C., Roux, C., Wakeham, A. C., Göbl, C., Zhou, W., Jafari, S. M., Snow, B. E., Jones, L., Palomero, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815126116 · Cited by 116
Self-citationLong noncoding RNA: a dazzling dancer in tumor immune microenvironment
Zhang, Y., Liu, Q., & Liao, Q. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01727-3 · Cited by 112
Huggins, D. N., LaRue, R. S., Wang, Y., Knutson, T. P., Xu, Y., Williams, J. W., & Schwertfeger, K. L. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0101 · Cited by 111
Su, X., Xu, Y., Fox, G. C., Xiang, J., Kwakwa, K. A., Davis, J. L., Belle, J. I., Lee, W., Wong, W., Fontana, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145296 · Cited by 109
Targeting specific cells in the brain with nanomedicines for CNS therapies
Zhang, F., Lin, Y.-A., Kannan, S., & Kannan, R. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.013 · Cited by 113
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies
Sáinz, B., Carron, E. C., Vallespinós, M., & Machado, H. L. (2016) · Mediators of Inflammation · doi:10.1155/2016/9012369 · Cited by 115
Ge, H., Mu, L., Jin, L., Yang, C., Chang, Y. E., Yu, L., DeLeon, G., Deleyrolle, L. P., Mitchell, D. A., Kubilis, P. S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30830 · Cited by 109
A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours
Cui, C., Chakraborty, K., Tang, X. A., Schoenfelt, K. Q., Hoffman, A., Blank, A., McBeth, B., Pulliam, N., Reardon, C. A., Kulkarni, S., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00988-z · Cited by 113
Zhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 116
Coulton, A., Murai, J., Qian, D., Thakkar, K., Lewis, C. E., & Litchfield, K. (2024) · Nature Communications · doi:10.1038/s41467-024-49885-8 · Cited by 120
“TAMs have long been associated with therapeutic outcome 67,89,90 , including the response to immune checkpoint inhibitors (ICI) 91 .”
Guo, Q., Jin, Z., Yuan, Y., Liu, R., Xu, T., Wei, H., Xu, X., He, S., Chen, S., Shi, Z., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/6728474 · Cited by 108
Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review
Bozada, T., Borden, J., Workman, J., Del Cid, M., Malinowski, J., & Luechtefeld, T. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.685298 · Cited by 118
The emerging roles of macrophages in cancer metastasis and response to chemotherapy
Sanchez, L. R., Borriello, L., Entenberg, D. R., Condeelis, J. S., Oktay, M. H., & Karagiannis, G. S. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0218-056rr · Cited by 106
Racioppi, L., Nelson, E. R., Huang, W., Mukherjee, D., Lawrence, S. A., Lento, W. E., Masci, A. M., Jiao, Y., Park, S. H., York, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10424-5 · Cited by 104
Ramesh, A., Brouillard, A., Kumar, S., Nandi, D., & Kulkarni, A. A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119559 · Cited by 108
Liu, R., Hu, R., Zeng, Y., Zhang, W., & Zhou, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102602 · Cited by 106
Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
Wang, S., Li, Y., Cheng, X., Ding, C., Zhang, H., Chen, L., You, L., Dai, M., & Zhao, Y. (2020) · PubMed Central · Cited by 107
Heterogeneous origins and functions of mouse skeletal muscle-resident macrophages
Wang, X., Sathe, A. A., Smith, G. R., Ruf-Zamojski, F. M., Nair, V., Lavine, K. J., Xing, C., Sealfon, S. C., & Zhou, L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915950117 · Cited by 120
Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Wang, G., Zhang, M., Cheng, M., Wang, X., Li, K., Chen, J., Chen, Z., Chen, S., Chen, J., Xiong, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.009 · Cited by 113
Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer
Xiao, M., He, J., Yin, L., Chen, X., Zu, X., & Shen, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799428 · Cited by 110
Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies
Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115036 · Cited by 112
Targeting C-Type Lectin Receptors for Cancer Immunity
Yan, H., Kamiya, T., Suabjakyong, P., & Tsuji, N. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00408 · Cited by 112
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Curran, E. K., Godfrey, J. K., & Kline, J. P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.004 · Cited by 108
Menck, K., Bleckmann, A., Wachter, A., Hennies, B., Ries, L., Schulz, M., Balkenhol, M., Pukrop, T., Schatlo, B., Rost, U., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1340745 · Cited by 106
Bartneck, M., Schrammen, P. L., Möckel, D., Govaere, O., Liepelt, A., Krenkel, O., Ergen, C., McCain, M. V., Eulberg, D., Luedde, T., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.007 · Cited by 110
Li, H., Somiya, M., & Kuroda, S. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120601 · Cited by 107
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 114
Chronic Inflammation’s Transformation to Cancer: A Nanotherapeutic Paradigm
Sohrab, S. S., Raj, R., Nagar, A., Hawthorne, S. J., Paiva‐Santos, A. C., Kamal, M. A., El-Daly, M. M., Azhar, E. I., & Sharma, A. (2023) · Molecules · doi:10.3390/molecules28114413 · Cited by 116
Pal, R., Chakraborty, B., Nath, A., Singh, L. M., Ali, M. A., Rahman, D. S., Ghosh, S. K., Basu, A., Bhattacharya, S., Baral, R., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.06.006 · Cited by 110
Miyasato, Y., Shiota, T., Ohnishi, K., Pan, C., Yano, H., Horlad, H., Yamamoto, Y., Yamamoto‐Ibusuki, M., Iwase, H., Takeya, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13287 · Cited by 106
Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages
Yao, Z., Zhang, J., Zhang, B., Liang, G., Chen, X., Yao, F., Xu, X., Wu, H., He, Q., Ding, L., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.05.002 · Cited by 106
Unraveling the ECM-Immune Cell Crosstalk in Skin Diseases
Bhattacharjee, O., Ayyangar, U., Kurbet, A. S., Ashok, D., & Raghavan, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00068 · Cited by 109
Ye, Y., Zhao, J., Lu, Y., Gao, C.-C., Yang, Y., Liang, S.-Q., Lu, Y., Wang, L., Yue, S., Dou, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1691 · Cited by 107
Wang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 122
“Numerous studies indicate that M1-polar-ized macrophages generate pro-inflammatory cytokines and inhibit malignancy progression, while M2-polarized cells produce tumor growth factors (IL-6), angiogenic molecules (VEGF), and immunosuppressive agents (Arg1, IL-10, TGF-b, and IDO) [233].”
Cornelissen, R., Hegmans, J. P., Maat, A. P. W. M., Kaijen-Lambers, M. E. H., Bezemer, K., Hendriks, R. W., Hoogsteden, H. C., & Aerts, J. G. J. V. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1573oc · Cited by 105
Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis
Yin, M., Shen, J., Yu, S., Jing, F., Zhu, X., Zhao, J., Zhai, L., Sadhukhan, A., & Zhou, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216355 · Cited by 108
MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis
Meškytė, E. M., Keskas, S., & Ciribilli, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207710 · Cited by 109
Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment
Mun, J.-Y., Leem, S., Lee, J. H., & Kim, H. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864739 · Cited by 113
Targeting endothelial permeability in the EPR effect
Lahooti, B., Akwii, R. G., Zahra, F. T., Sajib, M. S., Λάμπρου, Μ., Alobaida, A., Lionakis, M. S., Mattheolabakis, G., & Mikelis, C. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.039 · Cited by 114
Targeting the immune microenvironment for ovarian cancer therapy
Blanc‐Durand, F., Xian, L. C. W., & Tan, D. S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1328651 · Cited by 115
“They effectively modulate effector T-cell proliferation [through the expression of PD-L1 and CTLA4 receptors and arginase-1 (ARG1) activity] and enhance Tregs recruitment (mediated by CCL22) (81, 82).”
BackgroundChemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
A Milestone Review on How Macrophages Affect Tumor Growth
Caux, C., Ramos, R. N., Prendergast, G. C., Bendriss‐Vermare, N., & Ménétrier‐Caux, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2631 · Cited by 103
Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers · doi:10.3390/cancers11050714 · Cited by 103
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 105
Individualized precision treatment: Targeting TAM in HCC
Li, Z., Wu, T., Zheng, B. J., & Chen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.019 · Cited by 101
Zhou, L., Jiang, Y., Liu, X., Li, L., Yang, X., Dong, C., Liu, X., Lin, Y., Yan, L., Yu, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0840-4 · Cited by 102
Wang, Q., Gao, J., Di, W. J., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02576-x · Cited by 104
Tumor‐associated macrophages in immunotherapy
Yan, S., & Wan, G. (2021) · FEBS Journal · doi:10.1111/febs.15726 · Cited by 105
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Amino-acid sensing and degrading pathways in immune regulation
Grohmann, U., Mondanelli, G., Belladonna, M. L., Orabona, C., Pallotta, M. T., Iacono, A., Puccetti, P., & Volpi, C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.004 · Cited by 105
Tumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 103
Kim, H., Cha, J., Jang, M., & Kim, P. (2019) · Biomaterials Science · doi:10.1039/c9bm00155g · Cited by 106
Chen, W., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., & Xiong, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198126 · Cited by 107
Metadata
- Authors
- Noy, R., & Pollard, J. W.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pollard, Jeffrey W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 41
- Issue
- 1
- Pages
- 49-61
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4137410
- OpenAlex
- W1971620413
- Cited by
- 4,089
- References
- 136
- Citations by year
- 2026: 258 · 2025: 326 · 2024: 359 · 2023: 393 · 2022: 485 · 2021: 479 · 2020: 424 · 2019: 379 · 2018: 297 · 2017: 285 · 2016: 215 · 2015: 157 · 2014: 27
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (101067, 101067/Z/13/Z)
- National Institutes of Health (UL1TR001073)
- National Cancer Institute (P01CA100324, R01CA172451)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-associated macrophages, tumor microenvironment, tumor angiogenesis, tumor invasion, metastasis, pre-metastatic niche, immunosuppression, natural killer cells, T cells, macrophage-targeted therapy, combination cancer therapy
- MeSH terms
- Animals, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Humans, Immunosuppression Therapy, Macrophages, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Cell Lineage, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
